Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF)and may include paid advertising.
- The company has appointed Chilean drug policy specialist Felipe Leyton to lead commercialization in South America’s mining industry.
- The company is preparing to deploy its voice-based AI drug and alcohol impairment detection platform in industrial environments beginning in 2026, with Chile’s mining sector, employing more than 200,000 workers, representing an early target market.
- MindBio’s technology analyzes voice patterns to detect intoxication or impairment without biological testing, and management is positioning the platform as a scalable tool for workplace safety in mining and other high-risk industries.
- The company also recently closed an upsized non-brokered private placement of up to $1.5 million to support commercialization activities.
MindBio Therapeutics (CSE: MBIO) (OTCQB: MBQIF), a biotechnology innovator commercializing AI-powered voice analytics for real-time drug and alcohol impairment detection, is moving toward commercial deployment of its voice-based artificial intelligence platform for detecting drug and alcohol impairment, with a focus on industrial safety applications in South America’s mining sector.
The biotechnology company recently appointed Chilean policy specialist Felipe Leyton to lead commercialization efforts in the region, a move that signals MindBio’s transition from…
NOTE TO INVESTORS: The latest news and updates relating to MBQIF are available in the company’s newsroom at https://ibn.fm/MBQIF
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
